IGF-1 LR3

Research protocols typically use 50-100 mcg/day subcutaneous injection for 4-6 weeks, with a maximum of 8 weeks continuous use to avoid receptor desensitization and insulin sensitivity issues. Not FDA-approved for human use. Can cause hypoglycemia at higher doses.

Binds to and activates the IGF-1 receptor (IGF-1R), triggering downstream anabolic signaling cascades including PI3K/Akt and MAPK/ERK pathways.

The arginine substitution at position 3 reduces binding affinity for IGF-binding proteins, resulting in higher free IGF-1 bioavailability and extended biological activity.

Directly activates muscle satellite (stem) cells responsible for repairing and building new muscle fibers, promoting both hyperplasia and hypertrophy.

Enhances glucose uptake in muscle cells through insulin-receptor-like signaling, which can lower blood sugar levels.

Drives muscle development through hyperplasia (increasing muscle cell numbers) and mitogenesis (developing new muscle fibers), promoting true hypertrophy.

Extended bioavailability supports continuous anabolic effects, promoting faster muscle repair and recovery from exercise or injury.

May promote fat oxidation and improved body composition through enhanced metabolic activity and nutrient partitioning.

Promotes cellular growth, proliferation, and differentiation across multiple tissue types including muscle, bone, and connective tissue.

Study 41015370

Study 39679943

Study 39610283